Jazz Pharmaceuticals plc (JAZZ) Jumps Nearly 30% on Strong Q3 and Cancer Drug Trial Progress

3 weeks ago 18

Attiya Zainib

Fri, February 27, 2026 astatine 7:51 AM CST 3 min read

The Harbor Capital Advisors released its “Mid Cap Value Fund’s” Q4 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. Harbor Mid Cap Value Fund, subadvised by LSV Asset Management, delivered coagulated outperformance successful the 4th fourth of 2025, with the Institutional Class returning 4.07% versus 1.42% for the Russell Midcap Value Index, benefiting from spot successful worth stocks arsenic the Russell Midcap Growth Index declined 3.7% during the period. U.S. equities broadly advanced, with the S&P 500 Index rising 2.7% successful the 4th and 17.9% for the afloat year, portion mid-caps lagged, with the Russell Midcap Index up conscionable 0.2% successful Q4. For 2025, the Fund gained 15.95% (Institutional Class), outperforming the benchmark’s 11.05% return. Attribution information amusement a full quarterly excess instrumentality of 2.82%, mostly from enactment effects, underscoring the manager’s quantitative worth subject focused connected cardinal undervaluation, improving momentum, and hazard control. Looking ahead, absorption noted that portion AI-driven large-cap enactment has elevated valuations successful definite segments, mid- and small-cap worth stocks proceed to commercialized astatine much charismatic multiples, positioning the Fund to capitalize connected opportunities wrong economically delicate and cash-generative businesses. In addition, delight cheque the Fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its fourth-quarter 2025 capitalist letter, Harbor Capital Advisors' Mid Cap Value Fund highlighted stocks similar Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is simply a biopharmaceutical institution specializing successful treatments for slumber disorders, epilepsy, and oncology with a absorption connected high-value specialty medicines. The one-month instrumentality of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was 14.88% portion its shares traded betwixt $95.49 and $198.00 implicit the past 52 weeks. On February 26, 2026, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) banal closed astatine astir $188.97 per share, with a marketplace capitalization of astir $11.483 billion.

Harbor Capital Advisors' Mid Cap Value Fund stated the pursuing regarding Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in its Q4 2025 capitalist letter:

"Jazz Pharmaceuticals plc (NASDAQ:JAZZ), successful the Health Care sector, was a apical performer, advancing astir 30% driven by beardown 3rd 4th show and affirmative objective proceedings results for 1 of its crab drugs. We proceed to clasp the institution successful the Fund."

wavebreakmedia/Shutterstock.com

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. As per our database, 64 hedge money portfolios held Jazz Pharmaceuticals plc (NASDAQ:JAZZ) astatine the extremity of the 4th quarter, which was 49 successful the erstwhile quarter. While we admit the hazard and imaginable of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) arsenic an investment, our condemnation lies successful the content that immoderate AI stocks clasp greater committedness for delivering higher returns and doing truthful wrong a shorter clip frame. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article